Bortezomib, Lenalidomide, and Dexamethasone in Elderly Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Clin Lymphoma Myeloma Leuk. 2020 Dec;20(12):e986-e989. doi: 10.1016/j.clml.2020.08.002. Epub 2020 Aug 5.

Authors

Claude Chahine¹, Damien Roos-Weil², Véronique Saada³, Stéphane de Botton¹, Jean-Baptiste Micol¹, Stéphane Barete⁴, Christophe Marzac³, David Ghez⁵

Affiliations

¹ Department of Hematology, Gustave Roussy, Cancer Campus, Villejuif, France.
² Department of Hematology, Hôpital de la Pitié Salpetriere, Paris, France.
³ Department of Biology, Gustave Roussy, Cancer Campus, Villejuif, France.
⁴ Department of Dermatology, Hôpital de la Pitié Salpetriere, Paris, France.
⁵ Department of Hematology, Gustave Roussy, Cancer Campus, Villejuif, France. Electronic address: [email protected].

PMID: 32917576
DOI: 10.1016/j.clml.2020.08.002

No abstract available

Keywords: Allogeneic stem-cell transplantation; IMID; Leukemia; Proteasome inhibitor.

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bortezomib / pharmacology
Bortezomib / therapeutic use*
Dendritic Cells / metabolism*
Dexamethasone / pharmacology
Dexamethasone / therapeutic use*
Hematologic Neoplasms / drug therapy*
Humans
Lenalidomide / pharmacology
Lenalidomide / therapeutic use*
Male

Substances

Bortezomib
Dexamethasone
Lenalidomide